CYTOPOINT™ is a novel monoclonal antibody (mAb) therapy licensed by the USDA to help reduce clinical signs associated with atopic dermatitis in dogs.  As a mAb, CYTOPOINT is specifically designed to target and neutralize cytokine IL-31, a key itch-inducing cytokine in canine atopic dermatitis.Did you enjoy this track? Listen & learn more at wvc.org/resources

CYTOPOINT™ is a novel monoclonal antibody (mAb) therapy licensed by the USDA to help reduce clinical signs associated with atopic dermatitis in dogs. As a mAb, CYTOPOINT is specifically designed to target and neutralize cytokine IL-31, a key itch-inducing cytokine in canine atopic dermatitis.Did you enjoy this track? Listen & learn more at wvc.org/resources

CYTOPOINT™ is a novel monoclonal antibody (mAb) therapy licensed by the USDA to help reduce clinical signs associated with atopic dermatitis in dogs.  As a mAb, CYTOPOINT is specifically designed to target and neutralize cytokine IL-31, a key itch-inducing cytokine in canine atopic dermatitis.Did you enjoy this track? Listen &amp; learn more at wvc.org/resources

CYTOPOINT™

ENHANCING ANIMAL & HUMAN HEALTH WORLDWIDEWVC is dedicated to providing quality continuing education to medical professionals through an array of learning styles and environments. Our courses provide comprehensive, progressive and practical knowledge that can be immediately applied and implemented into practice.

Business

Education

Self-Improvement

Non-Profit

ENHANCING ANIMAL &amp; HUMAN HEALTH WORLDWIDEWVC is dedicated to providing quality continuing education to medical professionals through an array of learning styles and environments. Our courses provide comprehensive, progressive and practical knowledge that can be immediately applied and implemented into practice.

Share CYTOPOINT™

Sign up to save your podcasts

CYTOPOINT™

CYTOPOINT™